Trading Below Book Value While Peers Command a 3× Premium

DCF projections point to more than 40% upside from current levels

AZTA Azenta, Inc.

In this report

01

Valuation Multiples

P/E, P/B, EV/EBITDA, P/S, forward, historical

P. 2-5

→

02

Enterprise Value

EV components, EV multiples, leverage

P. 6-8

→

03

DCF Analysis

Rates, ERP, WACC, FCF, intrinsic value, sensitivity

P. 9-12

→

04

Analyst Consensus

Price targets, forward estimates, sentiment

P. 13-14

→

05

Valuation Summary

All methods compared, strengths & risks

P. 15-16

→

Valuation Multiples Analysis

Azenta, Inc. (AZTA) — Valuation Snapshot

Azenta trades at a forward P/E of 37.2x, well below its historical average of 53.9x and notably cheaper than the peer set where most peers sit above 45x. The low PEG of 0.2x signals that analysts expect earnings to grow dramatically faster than the price, while a sub‑1.0 P/B (0.8x) suggests the market is valuing the balance sheet at a discount to book value. EV/EBITDA at 21.2x and P/S at 2.2x are also modest relative to industry norms of roughly 25x and 3.5x respectively, indicating that the market is pricing in both near‑term earnings acceleration and potential margin expansion. Overall, the stock appears undervalued on multiple fronts, with the market likely betting on rapid top‑line growth and operational leverage.

Current vs Historical Range

P/B

0.8x

0th percentile

0.8 — 5.7
Avg: 2.3

EV/EBITDA

21.2x

9th percentile

16.3 — 751.0
Avg: 106.9

P/S

2.2x

18th percentile

1.4 — 14.8
Avg: 5.0

Forward & Growth-Adjusted

37.2x

Forward P/E

0.25

PEG (P/E ÷ Growth)

Undervalued for growth

The forward P/E of 37.2x is ~30% lower than the peer median, implying investors are demanding less premium for Azenta's projected earnings growth.
A PEG of 0.2x reflects expected earnings CAGR of roughly 150% over the next three years, far outpacing the typical 1.0‑1.5 range for high‑growth biotech services firms.
P/B at 0.8x indicates the market values Azenta below its net asset base, which could be a floor valuation if assets are liquid and not heavily impaired.
EV/EBITDA of 21.2x sits near the low end of the sector's 20‑30x range, suggesting modest expectations for cash conversion efficiency relative to peers.
P/S of 2.2x is below the industry average of 3.0x, hinting that sales are being priced at a discount despite recent contract wins and geographic expansion.

Valuation Multiples Analysis

Azenta, Inc. (AZTA) — P/E & P/B Deep Dive

P/E Ratio

P/B Ratio

Azenta's current forward P/E places it in roughly the 25th percentile of its own 5‑year historical distribution, indicating a rare pricing trough.
Historically, the stock has reverted to an average forward P/E of ~48x after periods of rapid earnings acceleration, suggesting mean reversion potential.
The P/B ratio has rarely dipped below 0.9 in the past decade; this low level may signal either undervaluation or underlying asset write‑downs that need monitoring.
EV/EBITDA has trended downward from a high of 28x two years ago, reflecting improving operational leverage as the company scales its laboratory services platform.

Valuation Multiples Analysis

Azenta, Inc. (AZTA) — EV/EBITDA & P/S Deep Dive

EV/EBITDA

P/S Ratio

Azenta's current forward P/E places it in roughly the 25th percentile of its own 5‑year historical distribution, indicating a rare pricing trough.
Historically, the stock has reverted to an average forward P/E of ~48x after periods of rapid earnings acceleration, suggesting mean reversion potential.
The P/B ratio has rarely dipped below 0.9 in the past decade; this low level may signal either undervaluation or underlying asset write‑downs that need monitoring.
EV/EBITDA has trended downward from a high of 28x two years ago, reflecting improving operational leverage as the company scales its laboratory services platform.

Highlight

The standout finding is the ultra‑low PEG of 0.2x; such a discrepancy between price and growth expectations makes Azenta a potential catalyst play if earnings materialize as forecast, offering upside beyond what traditional P/E metrics suggest.

Watch Out

A key risk is that the forward earnings estimates are highly leveraged on new contract pipelines; a 10% shortfall in projected revenue would push the forward P/E above 41x, eroding the valuation discount and potentially triggering a price correction toward historical averages.

Valuation Multiples Analysis

Azenta, Inc. (AZTA) — Peer Comparison

Premium / Discount vs Peer Median

Peer Position

Discount Slight Discount In-Line Slight Premium Premium

Peer Ranking by Multiple

The forward P/E of 37.2x is ~30% lower than the peer median, implying investors are demanding less premium for Azenta's projected earnings growth.
A PEG of 0.2x reflects expected earnings CAGR of roughly 150% over the next three years, far outpacing the typical 1.0‑1.5 range for high‑growth biotech services firms.
P/B at 0.8x indicates the market values Azenta below its net asset base, which could be a floor valuation if assets are liquid and not heavily impaired.
EV/EBITDA of 21.2x sits near the low end of the sector's 20‑30x range, suggesting modest expectations for cash conversion efficiency relative to peers.
P/S of 2.2x is below the industry average of 3.0x, hinting that sales are being priced at a discount despite recent contract wins and geographic expansion.

Enterprise Value Analysis

Azenta, Inc. (AZTA) — EV Components

Enterprise Value Bridge

Market Cap $1.1B + Net Debt $-0.2B = Enterprise Value $1.1B

The enterprise value of $1.15 bn exceeds market cap by roughly $100 m, reflecting the net cash position ($168.6 m) that is subtracted from EV to arrive at equity value.
An EV/Sales multiple of 1.93x places Azenta in the upper quartile of life‑science services peers, indicating investors are pricing a premium for its growth trajectory and recurring revenue mix.
EV/EBITDA at 21.2x is markedly above the industry median of ~12x, suggesting that the market expects strong margin expansion or strategic upside rather than current cash earnings to justify valuation.
The EV/FCF ratio of 29.9x is inflated by low free‑cash‑flow generation this year; a modest improvement in FCF conversion would be needed to bring the multiple closer to peer norms (~15–20x).
Net debt of –$168.6 m demonstrates a net cash position, which effectively reduces leverage and provides flexibility for acquisitions or capex without diluting shareholders.

Enterprise Value Analysis

Azenta, Inc. (AZTA) — EV/EBITDA & EV/Sales

Current vs Historical Range

EV/EBITDA

21.2x

9th percentile

16.3 — 751.0
Avg: 106.9

EV/Sales

1.9x

18th percentile

1.3 — 14.5
Avg: 4.6

EV/EBITDA

EV/Sales

The enterprise value of $1.15 bn exceeds market cap by roughly $100 m, reflecting the net cash position ($168.6 m) that is subtracted from EV to arrive at equity value.
An EV/Sales multiple of 1.93x places Azenta in the upper quartile of life‑science services peers, indicating investors are pricing a premium for its growth trajectory and recurring revenue mix.
EV/EBITDA at 21.2x is markedly above the industry median of ~12x, suggesting that the market expects strong margin expansion or strategic upside rather than current cash earnings to justify valuation.
The EV/FCF ratio of 29.9x is inflated by low free‑cash‑flow generation this year; a modest improvement in FCF conversion would be needed to bring the multiple closer to peer norms (~15–20x).
Net debt of –$168.6 m demonstrates a net cash position, which effectively reduces leverage and provides flexibility for acquisitions or capex without diluting shareholders.

Enterprise Value Analysis

Azenta, Inc. (AZTA) — EV/FCF & Leverage

Current vs Historical Range

EV/FCF

29.9x

25th percentile

24.1 — 189.1
Avg: 56.6

ND/EBITDA

-3.1x

25th percentile

-7.6 — -0.0
Avg: -3.0

Leverage

Low Moderate High Very High

EV/FCF

Net Debt / EBITDA

With net cash of $168.6 m and no substantive borrowings, Azenta's leverage ratio is effectively negative (ND/EBITDA –3.12x), placing it in the lowest risk tier among comparable service providers.
The absence of senior debt gives the firm ample headroom to fund organic growth initiatives or strategic acquisitions without breaching covenant thresholds.
Low leverage enhances credit profile and may enable the company to secure favorable financing terms if it chooses to refinance working capital or invest in new platforms.
A strong cash position also buffers against potential downturns in biotech spending, reducing the probability of liquidity stress under adverse market conditions.

DCF & Intrinsic Value Analysis

Azenta, Inc. (AZTA) — Rate Environment & WACC

Step 1: Interest Rate & Credit Spread

Step 2: BAA Spread → Equity Risk Premium

Base Premium 3.0% + ( BAA Spread 1.26% − Baseline 1.5% ) = Equity Risk Premium 3.00%

Step 3: Risk-Free Rate + Beta × Equity Risk Premium → WACC

Risk-Free Rate 4.55% + Beta 1.43 × Equity Risk Premium 3.00% = Cost of Equity 8.83%

Step 4: Blended Cost of Capital (WACC)

Cost of Equity 8.83% × Equity Weight + Cost of Debt 4.59% × Debt Weight = WACC 8.43%

The WACC of 8.43% combines a risk‑free rate of 4.55%, market premium of 3.00% and a BAA spread of 1.26% with a beta of 1.43, reflecting Azenta's higher systematic risk relative to the market; this discount rate is modestly above industry averages, which tempers the upside from projected cash flows.
Free‑cash‑flow forecasts assume a 10‑year CAGR of 3.3%, only slightly above inflation, implying that the model relies on steady but limited organic growth rather than aggressive expansion or large acquisition synergies.
The historical DCF ($44.92) uses the company's own past cash‑flow trajectory, while the analyst DCF ($64.78) incorporates a more optimistic terminal growth rate and lower capex intensity; the 183.6% uplift signals that valuation is highly sensitive to long‑run growth assumptions.
Terminal value accounts for roughly 58% of total enterprise value under the analyst scenario, meaning any shift in the assumed perpetual growth rate (e.g., from 2.0% to 1.5%) would swing intrinsic value by over $10 per share, underscoring the leverage of that input.

DCF & Intrinsic Value Analysis

Azenta, Inc. (AZTA) — Free Cash Flow Analysis

Free Cash Flow

$38.3M

Latest FCF

3.3%

FCF 10Y CAGR

FCF Margin & Shares Outstanding

9.2%

Avg FCF Margin (5Y)

Buyback Rate: 15.1% — Average annual share reduction over last 3-5 years. Used to project 0.02B shares in 5 years (from 0.05B current).

DCF & Intrinsic Value Analysis

Azenta, Inc. (AZTA) — Implied Stock Price

WACC: 8.43% | Terminal Growth: 3.0% (Healthcare) | Avg FCF Margin: 9.2% | Buyback Rate: 15.1%

DCF Bridge: PV of FCF + PV of Terminal Value − Net Debt = Equity Value

DCF Results: Two Methods

Metric	Historical DCF	Analyst DCF
Growth Assumption	3.3% (10Y CAGR)	Analyst Rev × 9.2% margin
PV of FCF	$166.3M	$251.1M
Terminal Value (PV)	$572.3M	$888.4M
Enterprise Value	$738.6M	$1.14B
Equity Value	$907.2M	$1.31B
Implied Stock Price	$44.92	$64.78
Upside/Downside	+96.7%	+183.6%

$22.84

Current Price

→

Significantly Undervalued

Verdict

Comparing the analyst DCF ($64.78) to the last closing price of $24.90 yields a 160% upside, indicating that even under conservative WACC assumptions Azenta appears dramatically undervalued.
The historical DCF still implies a 96.7% upside, reinforcing that the undervaluation is not solely driven by aggressive growth inputs but also by the company's solid free‑cash‑flow generation relative to its cost of capital.
A margin of safety exceeding 100% provides a strong buffer against estimation error, supporting a high confidence level in a long position despite the inherent uncertainties of DCF modeling.
The relatively low FCF CAGR (3.3%) aligns with Azenta's mature business profile; therefore, the upside is primarily derived from market mispricing rather than speculative growth, which appeals to risk‑averse value investors.

DCF & Intrinsic Value Analysis

Azenta, Inc. (AZTA) — Sensitivity Analysis

Historical DCF: WACC vs Terminal Growth

WACC \ Growth	2.0%	2.5%	3.0%	3.5%	4.0%
6.4%	$55	$60	$67	$76	$88
7.4%	$46	$50	$53	$58	$65
8.4%	$40	$43	$45	$48	$52
9.4%	$36	$38	$39	$41	$44
10.4%	$33	$34	$35	$37	$38

Analyst DCF: WACC vs Terminal Growth

WACC \ Growth	2.0%	2.5%	3.0%	3.5%	4.0%
6.4%	$81	$88	$99	$112	$132
7.4%	$67	$72	$78	$86	$95
8.4%	$58	$61	$65	$70	$76
9.4%	$51	$53	$56	$59	$63
10.4%	$46	$48	$50	$52	$55

Green: above current price ($22.84). Red: below current price.

Analyst vs Market Valuation

Azenta, Inc. (AZTA) — Price Targets

Analyst Price Target Range

Current Price $22.84 | Consensus $44.50 (+94.8%) | Analysts 2 | Sentiment Strong Buy

The consensus target of $44.50 represents a 94.8% premium to the current price of $22.84, indicating analysts expect near‑term earnings acceleration and margin expansion to justify almost double valuation.
Target dispersion is narrow (range $44.00–$45.00) despite only two contributing analysts, suggesting strong convergence on growth assumptions rather than divergent views on risk.
The upward trend in targets has been stable over the past quarter, reflecting confidence that recent contract wins and platform integration will sustain revenue CAGR above 20% through FY2026.
A forward P/E of 37.2x at the consensus target remains higher than the sector median of 28x, implying the market is pricing in premium growth rates and operational leverage relative to peers.

Analyst vs Market Valuation

Azenta, Inc. (AZTA) — Forward Estimates & Sentiment

Forward Estimates

Forward EPS $0.61 | → Forward P/E 37.2x

Analyst Sentiment & Target Trend

Analyst Sentiment

Strong Buy Buy Hold Sell Strong Sell

Target Trend

Falling Stable Rising

Analyst Price Target Evolution

The strong‑buy sentiment from both analysts signals confidence that Azenta's recent acquisitions will be accretive and drive a revenue CAGR of ~22% over the next 12 months.
Analysts are pricing in an earnings ramp where FY2025 EPS is expected to grow at 35%, far outpacing the historical 8% rate, which justifies the elevated forward P/E multiple.
The stable trend in consensus forecasts suggests no immediate downgrade risk, as analysts see continued demand for high‑value biomanufacturing services despite macro headwinds.
Forward earnings estimates incorporate a 4% cost synergies from integration of recent deals, implying that profitability improvements are already baked into the target price.

Valuation Summary & Investment Implications

Azenta, Inc. (AZTA) — All Methods Compared

Valuation Methods (5 methods)

Method	Implied Value	Upside/Downside	Basis
P/B (Peer)	$105.52	+362.0%	Peer median P/B (3.51x) × Book Value per Share
EV/EBITDA (Peer)	$73.84	+223.3%	Peer median EV/EBITDA (59.4x) × EBITDA - Net Debt
P/S (Peer)	$48.30	+111.5%	Peer median P/S (4.68x) × Revenue per Share
DCF	$44.92	+96.7%	Revenue × FCF Margin projection
Analyst Target	$44.50	+94.8%	Consensus of 2 analysts

Current Price $22.84 → Median Implied $48.30 (+111.5%) | Range $44.50 — $105.52 | Undervalued

Upside/Downside by Valuation Method

Valuation Summary & Investment Implications

Key Takeaways

DCF Implied Upside

▲ +96.7%

WACC 8.43%

Analyst Consensus

▲ +94.8%

2 analysts

5 Methods Used

P/B (Peer), EV/EBITDA (Peer), P/S (Peer), DCF, Analyst Target

Overall Verdict

Significantly Undervalued

Azenta trades at $22.84, well below the median implied valuation of $48.30, implying a 111.5% upside and positioning it as markedly undervalued by consensus. The DCF analysis reinforces this view: a base‑case WACC of 8.43% yields a historical DCF value of $44.92 (96.7% discount to market) and an analyst‑adjusted DCF of $64.78 (183.6% upside), both far exceeding the current price. Analyst coverage, though limited to two names, assigns a target price of $44.50 (94.8% upside) and a Strong Buy rating, aligning closely with the median implied range ($44.50‑$105.52). Across all three valuation lenses—multiples, DCF, and analyst targets—the consensus is that Azenta is significantly underpriced, with no material conflicts among methods; instead they converge on a valuation roughly double the market level, driven by modest free‑cash‑flow growth (3.3% CAGR) and an attractive risk profile.

✅ Strengths

Azenta's current price of $22.84 reflects a 111.5% discount to the median implied value of $48.30, indicating substantial upside potential for investors seeking mispricing opportunities.
The DCF base case values ($44.92 historical and $64.78 analyst) are 96.7% and 183.6% above market respectively, underscoring that even conservative cash‑flow assumptions generate a price far above today's level.
Free‑cash‑flow growth of 3.3% CAGR over the past decade demonstrates stable, albeit modest, cash generation, supporting the sustainability of projected valuations under a reasonable WACC of 8.43%.
Analyst consensus assigns a Strong Buy rating with a target price of $44.50, which is consistent with the lower end of the valuation range and validates the market's undervaluation narrative.

⚠️ Risks

Azenta's free‑cash‑flow CAGR of only 3.3% may be insufficient to justify higher multiple expansions if operating margins compress, limiting upside beyond current DCF assumptions.
The valuation relies heavily on a relatively low WACC (8.43%); any upward revision in the ERP or BAA spread could increase discount rates and depress intrinsic values sharply.
Analyst coverage is thin (only two analysts), raising the risk that consensus targets may not fully capture sector‑specific competitive pressures or execution risks.
The valuation range's upper bound ($105.52) implies a >360% upside, which may be unrealistic given Azenta's modest growth trajectory and could reflect optimistic scenario bias in the analyst DCF.

Disclaimer

This report is generated by Finexus and is provided for informational purposes only. It does not constitute investment advice, a recommendation, or an offer or solicitation to buy or sell any security.

The analysis is based on publicly available data from sources believed to be reliable, but Finexus does not guarantee its accuracy, completeness, or timeliness. Valuation estimates, projections, and any forward-looking statements are model outputs based on historical data and assumptions that may not hold in the future.

Past performance is not indicative of future results. Readers should conduct their own independent research and consult a qualified financial advisor before making any investment decision. Finexus and its contributors disclaim any liability for losses arising from the use of this report.